The following is a compendium of articles and op-eds I have written since 2013. It is an updated version of "Analyzing The Opioid Crisis: 65 Articles By Dr. Josh Bloom," which was published in 2019.
Back in 2019 I did an April Fool's Day 'interview' with Andrew Kolodny. Many of you enjoyed it. He did not. Here's a new one. Have fun!
In March I wrote about Phase IIa results of a novel NSAID-like drug ATB-346 (now called otenaproxesul), which is structurally and functionally similar to naproxen (Aleve). But the non-opioid drug lacks its gastrointestinal side effects, especially ulcers. Now Phase IIb results are in and it still looks good. Will it become the first member of a novel class of pain drugs? We could sure use it. A summary of the company's report to shareholders.
We've been quite busy answering questions about coronavirus, UV light, and hand sanitizer.
When I wrote about "Magic Aleve" -- a derivative of Aleve/naproxen that appears to be both G.I.-friendly and a more potent analgesic/antiinflammatory than Aleve itself -- a number of questions arose. Dr. John Wallace, CSO of Antibe, which is developing the drug called ATB-346, kindly agreed to answer them.
There hasn't been a material advance in the pharmacological treatment of pain since the 1890s, when heroin and aspirin were invented. That may change if an experimental drug being developed by a Toronto-based drug company keeps performing in advanced clinical trials. This could be huge.
The denial of prescription analgesic medication to chronic pain patients has caused unnecessary suffering. But it has also driven up the suicide rate, trapping those who cannot bear to live without the drugs that have kept them functioning for years. ACSH advisor Red Lawhern, Ph.D., discusses the tragedy of intolerable pain.
A new study tells us that since Florida passed a law restricting post-surgical opioid prescriptions, there are fewer post-surgical opioid prescriptions being written. This and other brilliance. Ripe for the picking.
Dawn Anderson, a former nurse who was dying from multiple, painful conditions, faced far worse than just death. She was dying in agony, as hospital staff refused to provide opioid pain relievers that had worked well in the past. Here is Dawn's chilling story, which is the quintessential example of the consequences of "opioid madness" and the cruelty it brings with it.
Our ability to forget provides a survival advantage – while assuaging suffering in the process.
The knee is an incredibly complicated structure, which is why "knee pain" can be rather challenging to address. New research examines the physical distribution of knee pain and finds three common patterns.